Korean Cohort Study of AKI & HRS in Cirrhosis

Kidney Biomarkers for the Prediction of Response to Terlipressin and Survival in Cirrhotic Patients With Acute Kidney Injury: Multicenter, Prospective Cohort Study

The aim of this study is to investigate i) whether two biomarkers (urine NAG, urinary cystatin C) could be predictive factor in patient with liver cirrhosis, , and ii) whether these biomarkers can predict response of terlipressin.

Acute kidney injury (AKI) in patients with liver cirrhosis is sometimes accompanied by tubular injury which can lead to poor outcome. Current AKI criteria using serum creatinine (Cr) has some limitations to predict reversibility of renal function and discriminate renal parenchymal injury in cirrhotic patients. The aim of this study is to evaluate whether urine biomarkers [cystatin C, N-acetyl-β-D-Glucosaminidase (NAG)] can predict survival and response to terlipressin in cirrhotic patients with AKI.

Inclusion Criteria:

• Patients with liver cirrhosis diagnosed as acute kidney injury or hepatorenal syndrome
• Patients who voluntarily agreed to the study

Exclusion Criteria:

• Patients with active bleeding (eg, varix bleeding) within 7 days
• Patients with hepatocellular carcinoma
• Patients with hypersensitivity to terlipressin
• Patients with anuria
• Pregnant and lactating patients
• Patients who did not agree with the study